EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Latest Research Progress of IER3 in Clinical Significance and Mechanisms: Hepatocellular Carcinoma and Other Malignant Tumors

Wenbing Li, Xinlong Zhang, Yanting Yang, Zenghua Zhou, Zhenbo Huang, Hui Li

Clinical Medicine and Pharmacology · 2025

DOI: 10.70731/smem5v44 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Medicine and Pharmacology, 2025. Verfasst von Wenbing Li und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant tumor is one of the diseases threatening human health, and liver cancer is the most common. Hepatocellular carcinoma (HCC) is the most common clinicopathological subtype. Immediate early response 3 (IER3) plays a regulatory role in a variety of malignant tumors. This article reviews the latest research progress on the clinical significance and mechanism of IER3 in HCC and a variety of malignant tumors.

Zitieren

APA

Li, W., Zhang, X., Yang, Y., Zhou, Z., Huang, Z., & Li, H. (2025). The Latest Research Progress of IER3 in Clinical Significance and Mechanisms: Hepatocellular Carcinoma and Other Malignant Tumors. Clinical Medicine and Pharmacology. https://doi.org/10.70731/smem5v44

Vancouver

Li W, Zhang X, Yang Y, Zhou Z, Huang Z, Li H. The Latest Research Progress of IER3 in Clinical Significance and Mechanisms: Hepatocellular Carcinoma and Other Malignant Tumors. Clinical Medicine and Pharmacology. 2025. doi:10.70731/smem5v44

BibTeX
@article{Li2025,
  author = {Li, Wenbing and Zhang, Xinlong and Yang, Yanting and Zhou, Zenghua and Huang, Zhenbo and Li, Hui},
  title = {The Latest Research Progress of IER3 in Clinical Significance and Mechanisms: Hepatocellular Carcinoma and Other Malignant Tumors},
  journal = {Clinical Medicine and Pharmacology},
  year = {2025},
  doi = {10.70731/smem5v44}
}
Kostenlos starten →